Choroiditis in Systemic Lupus Erythematosus: Systemic Steroid Therapy and Focal Laser Treatment

2003 ◽  
Vol 47 (3) ◽  
pp. 312-315 ◽  
Author(s):  
M Shimura
Lupus ◽  
2019 ◽  
Vol 28 (12) ◽  
pp. 1473-1476 ◽  
Author(s):  
E Takamasu ◽  
N Yokogawa ◽  
K Shimada ◽  
S Sugii

Objective This study aimed to investigate the risk factors of hydroxychloroquine (HCQ)-induced hypersensitivity in patients with systemic lupus erythematosus (SLE) and to propose a simple dose-escalation regimen in cases of mild HCQ-induced hypersensitivity. Methods We identified patients with SLE who started HCQ between 2009 and 2018 and cases of HCQ-induced hypersensitivity by reviewing the electronic medical charts. A simple dose-escalation regimen, starting at 40 mg/day with weekly increments of 40 mg/day to 200 mg/day, was used in patients with HCQ-induced hypersensitivity who did not require hospitalization or systemic steroid therapy. We then compared the clinical parameters of patients with and without HCQ-induced hypersensitivity and evaluated the success of our dose-escalation regimen. Results We enrolled 302 patients with SLE and identified 25 cases of HCQ-induced eruption (8.3%). The mean Naranjo score of these patients was 5.1 ± 1.4 (min 3, max 8), and all 25 patients received a ‘possible’ (9) or ‘probable’ (16) score. A mild, generalized, maculopapular rash occurred in 24 patients, and urticaria occurred in one patient at 24 days (interquartile range 15–40 days) after the start of treatment. The proportion of cyclophosphamide use, glucocorticoid consisting of prednisolone 20 mg/day or more, and initiation of SMX-TMP within 28 days were higher in patients with skin eruptions. On multivariate analysis, only cyclophosphamide use was identified as a risk factor of HCQ-induced hypersensitivity (odds ratio = 12.3 (95% confidential interval 1.4–14.3)). Thirteen of the 14 patients on the dose-escalation regimen (92.9%) tolerated continued HCQ treatment. One patient re-experienced eruptions on day 10 day after starting HCQ. Conclusions Mild late reactions are common in HCQ-induced hypersensitivity. A simpler dose-escalation regimen enables safe and easier reintroduction of HCQ but should not be applied to patients with immediate reactions or moderate late reactions.


1986 ◽  
Vol 233 (3) ◽  
pp. 188-189 ◽  
Author(s):  
C. A. F. Zerbini ◽  
T. S. A. Fidelix ◽  
G. D. Rabello

2005 ◽  
Vol 68 (2) ◽  
pp. 747-759 ◽  
Author(s):  
Brad H. Rovin ◽  
Yuxiao Tang ◽  
Junfeng Sun ◽  
Haikady N. Nagaraja ◽  
Kevin V. Hackshaw ◽  
...  

1965 ◽  
Vol 8 (2) ◽  
pp. 244-259 ◽  
Author(s):  
Kurt Lange ◽  
Richard Ores ◽  
Walter Strauss ◽  
Max Wachstein†

2019 ◽  
Vol 5 (1) ◽  
Author(s):  
Atsushi Gakuhara ◽  
Yasuhiro Miyazaki ◽  
Yukinori Kurokawa ◽  
Tsuyoshi Takahashi ◽  
Makoto Yamasaki ◽  
...  

Abstract Background Systemic lupus erythematosus (SLE), an autoimmune disease characterized by systemic inflammatory lesions, is often associated with obesity. Obesity aggravates symptoms of SLE; however, these symptoms can be improved by weight loss through diet therapy and bariatric surgery. However, there are only a few reports regarding the effectiveness of bariatric surgery in obese patients with SLE. Herein, we discuss the laparoscopic sleeve gastrectomy (LSG) performed in an obese patient with SLE while undergoing long-term steroid therapy. Case presentation A 36-year-old female, suffering from SLE for 10 years with effects on the central nervous system, developed diabetes mellitus (DM) triggered by the steroid therapy for SLE. The patient was undergoing steroid therapy (6 mg/day) for SLE since a long time. For DM management, her HbA1c level was maintained at 7.4%. She was 158 cm tall and 91.6 kg in weight. Her body mass index was 36.7. She could not work and depended on welfare services. To improve her obesity and DM, physicians suggested that she should undergo bariatric surgery in our hospital. Eventually, she underwent LSG, which lasted for 185 min, with minimal blood loss and without complications. Her blood glucose level stabilized immediately after the surgery; hence, her antidiabetic medication was discontinued. She was discharged 8 days after surgery, and her weight decreased steadily. In the first year after surgery, her weight was 54.4 kg, and she had lost approximately 37 kg from her initial weight. Her steroid requirement had also reduced to 4 mg/day. Through weight loss, she could begin to work and became a part of society again. Conclusion LSG was safely performed in an obese patient with SLE undergoing long-term steroid therapy. We noted substantial weight loss, improved DM condition, and reduced requirement of SLE therapy after surgery. Hence, surgical risks must be carefully examined before patients undergo bariatric surgery.


Sign in / Sign up

Export Citation Format

Share Document